Retrospective Real-word Study of Linezolid for the Treatment of Tuberculous Meningitis

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Total Enrollment

150 participants

Study Classification

OBSERVATIONAL

Study Start Date

2018-01-01

Study Completion Date

2019-06-01

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Tuberculous meningitis (TBM) is the most serious form of Mycobacterium tuberculosis infection, causing mortality and disability in more than half of the patients. Current standard treatment for TBM is based on those developed to treat pulmonary tuberculosis, which does not take into account the differential ability of anti-tuberculosis drugs to penetrate the brain. With both good central nervous system penetrance and anti-tuberculosis efficacy that have been demonstrated in drug-resistant tuberculosis, linezolid may be a promising antimicrobial in TBM treatment. The purpose of this study is to evaluate the effectiveness of linezolid in the treatment of TBM.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Phase II Clinical Study of Contezolid for the Treatment of Tuberculous Meningitis

NCT06811025

Tuberculosis Meningitis

ENROLLING_BY_INVITATION PHASE1/PHASE2

Pharmacokinetic Study of Linezolid for TB Meningitis

NCT03537495

Tuberculosis, Meningeal Linezolid

COMPLETED PHASE2

Trial of a Six-Month Regimen of High-Dose Rifampicin, High-Dose Isoniazid, Linezolid, and Pyrazinamide Versus a Standard Nine-Month Regimen for the Treatment of Adults and Adolescents With Tuberculous Meningitis

NCT05383742

Tuberculous Meningitis

RECRUITING PHASE2

Adjunctive Linezolid for the Treatment of Tuberculous Meningitis

NCT04021121

Tuberculosis, Meningeal

COMPLETED PHASE2

A Phase 2 Trial to Evaluate the Efficacy and Safety of Linezolid in Tuberculosis Patients. (LIN-CL001)

NCT02279875

Pulmonary Tuberculosis

COMPLETED PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Tuberculous Meningitis

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

RETROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Background group

The treatment regimen does not include linezolid throughout the treatment course.

No interventions assigned to this group

Background-linezolid group

Linezolid was added in the middle of the treatment course but not in the initial treatment regimen.

Linezolid

Intervention Type DRUG

To add linezolid 600mg or 1200mg daily in the initial or subsequent treatment regimen of TBM.

Linezolid initial group

Linezolid was in initial treatment regimen.

Linezolid

Intervention Type DRUG

To add linezolid 600mg or 1200mg daily in the initial or subsequent treatment regimen of TBM.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Linezolid

To add linezolid 600mg or 1200mg daily in the initial or subsequent treatment regimen of TBM.

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* all patients diagnosed as TBM from the electronic medical record system.

Exclusion Criteria

* Does not meet the established diagnostic criteria;
* Combine other pathogen central infections;
* Follow-up confirmed that the final diagnosis considers other diseases (such as tumors, autoimmune encephalitis, etc.);
* Our hospital has less than one week of anti-tuberculosis treatment;
* Lack of information

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No